FDA authorizes Labcorp’s direct-to-consumer test for RSV, the flu, and COVID-19


The Food and Drug Administration on Monday authorized a test developed by Laboratory Corporation of America Holdings LH, -0.92% that allows people in the U.S. to self-test for respiratory syncytial virus (RSV), a type of common cold, as well as the flu and COVID-19. The test does not require a prescription. People swab at home and send the test by mail to a Labcorp lab. Results are then made available in an online portal. Teens and children are also authorized to test with the support of adults. The test kit costs $169 and may be covered by insurance, according to a spokesperson. It is expected to be available within the next three weeks. Labcorp’s stock has tumbled 22.5% this year, while the broader S&P 500 SPX, -0.39% is down 15.5%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Twitter CEO fires back at Elon Musk
Next articleAbbott, FDA reach deal to resume making baby formula at U.S. plant amid shortage


Please enter your comment!
Please enter your name here